The second in a series of half-day virtual events focusing on practical approaches to management of gastrointestinal disorders and iron deficiency
Information intended for UK healthcare professionals only. This promotional event has been commissioned and funded by Norgine Pharmaceuticals Limited and developed in partnership with Guidelines. Promotional information regarding Norgine Pharmaceutical Limited products will be presented during these webinars.
UK-COR-NP-2100090
Date of preparation: October 2021
Half-day virtual event focusing on practical approaches to management of gastrointestinal disorders and iron deficiency
Information intended for UK healthcare professionals only. This promotional event has been commissioned and funded by Norgine Pharmaceuticals Limited and developed in partnership with Guidelines.
UK-COR-NP-2100043
Date of preparation: July 2021
Updates in best practice management of venous thromboembolism
These promotional videos have been funded by Bristol Myers Squibb on behalf of the BMS / Pfizer Alliance and developed in conjunction with Guidelines. The promotional content on this page is intended for UK healthcare professionals only.
View ELIQUIS (apixaban) prescribing and adverse event reporting information
432-GB-2100782 | Date of preparation: September 2021
Modern management of stroke prevention in non-valvular atrial fibrillation
These promotional videos have been funded by Bristol Myers Squibb on behalf of the BMS / Pfizer Alliance and developed in conjunction with Guidelines. The promotional content on this page is intended for UK healthcare professionals only.
View ELIQUIS (apixaban) prescribing and adverse event reporting information
432-GB-2100689 | Date of preparation: August 2021
The holistic management of patients requiring anticoagulation
This video has been commissioned and funded by Bayer plc and developed in partnership with Guidelines.
View Xarelto▼(rivaroxaban) prescribing information and adverse event reporting
PP-XAR-GB-1924 January 2021
Non-alcoholic steatohepatitis: identification, management, and referral pathways
The content on this page is intended for UK healthcare professionals only.
Identification of pancreatic exocrine insufficiency (PEI) in patients with diabetes
In this video, Su Down looks at the identification of PEI in patients with diabetes.
This video has been commissioned and funded by Viatris and developed in partnership with Guidelines. Information intended for UK healthcare professionals only.
NON-2020-3287 December 2020
Assessment of pancreatic exocrine insufficiency (PEI) in primary care
In this video, Professor Michael Cummings looks at the assessment of PEI in patients with diabetes.
This video has been commissioned and funded by Viatris and developed in partnership with Guidelines. Information intended for UK healthcare professionals only.
NON-2020-3288 December 2020
Management of pancreatic exocrine insufficiency (PEI) in primary care
In this video, Professor Michael Cummings looks at the management of PEI in patients with diabetes.
This video has been commissioned and funded by Viatris and developed in partnership with Guidelines. Information intended for UK healthcare professionals only.
NON-2020-3289 December 2020
Management of common eye conditions: blepharitis
Fiona Chiu (Moorfields Eye Hospital NHS Foundation Trust) explains the symptoms and management of blepharitis.
Management of common eye conditions: conjunctivitis
Sarah Thomas (Moorfields Eye Hospital NHS Foundation Trust) describes the causes, symptoms, and treatment of conjunctivitis.
Management of common eye conditions: dry eye
Fiona Chiu (Moorfields Eye Hospital NHS Foundation Trust) covers the presentation, causes, and treatment of dry eye.
Cancer support that complements your care - Macmillan’s Support Line can help your patients.
Our specialist advisers on the Macmillan Support Line can answer your patients’ questions after and in between appointments, or simply be there when they need a listening ear. Learn more here.
Empagliflozin (Jardiance®) 10mg film-coated tablets SMC2396
The production of this Guidelines summary card has been commissioned by the Boehringer Ingelheim and Lilly Alliance.
View Jardiance® (empagliflozin) prescribing and adverse event reporting information for Great Britain and Northern Ireland.
PC-GB-105816 October 2021
NICE Technology Appraisal 651: Naldemedine ▼ for treating opioid‑induced constipation
The production and printing of this Guidelines summary card has been commissioned by Sandoz Ltd. Information intended for UK healthcare professionals only.
View prescribing information
UK/P/RZM/20-0016c October 2020
Soolantra® (ivermectin) 10 mg/g cream
This prescribing summary card was developed from content provided by Galderma UK Ltd. Information intended for UK healthcare professionals only.
View Soolantra® (ivermectin) 10 mg/g cream prescribing and adverse event reporting information.
UKI-SOC-2100031 September 2021
Appropriate use of opioids for chronic pain in primary care
This promotional supplement has been commissioned and funded by Grünenthal and developed in partnership with Guidelines. Information intended for healthcare professionals only.
View PALEXIA® SR tablets (tapentadol hydrochloride) prescribing and adverse event reporting information
M-PLX-UK-10-21-0036 October 2021
Managing acne well—a summary of the 2021 NICE guideline
Information intended for UK healthcare professionals only. This promotional supplement has been commissioned and funded by Galderma and developed in partnership with Guidelines.
View Epiduo Gel 0.1% (0.1% adapalene & 2.5% benzoyl peroxide) prescribing information and adverse event reporting information.
View Epiduo Gel 0.3%/2.5 % (0.3% adapalene & 2.5% benzoyl peroxide) prescribing information and adverse event reporting information.
UKI-EDG-2100027
Date of preparation: October 2021
Prescribing hormone replacement therapy (HRT) in postmenopausal women: a focus on Oestrogel® (estradiol) and Utrogestan® 100 mg (micronised progesterone)
This prescribing supplement has been commissioned and funded by Besins Healthcare (UK) Ltd and developed in partnership with Guidelines. Includes promotional information.
View prescribing and adverse event reporting information
OES/2021/001a October 2021
For healthcare professionals only.
Recommending emollients for patients with atopic dermatitis or dry skin conditions
This supplement has been commissioned and funded by L’Oréal (UK) Limited and developed in partnership with Guidelines.
Date of preparation: January 2021
The importance of the progestogenic component of hormone replacement therapy in women with a uterus
Dr John Stevenson and Dr Sophia Tsiligiannis discuss progestogen prescribing in hormone replacement therapy.
Management of hepatic encephalopathy in primary care
This management algorithm has been commissioned and funded by Norgine Pharmaceuticals Limited and developed in partnership with Guidelines. Information intended for UK healthcare professionals only.
View TARGAXAN® (rifaximin-α) prescribing and adverse event reporting information
UK-HEP-XIF-2100040 October 2021
Guideline for the managed introduction of biosimilar bolus insulin in individuals with type 2 diabetes
This guideline was developed by a multidisciplinary expert panel: Down S et al with the support of an educational grant from Sanofi Ltd.
Prescribing combined hormone replacement therapy (HRT) containing dydrogesterone
This promotional algorithm has been commissioned and funded by Viatris and developed in partnership with Guidelines. Intended for UK healthcare professionals.
View Femoston® (estradiol/dydrogesterone) and Femoston® -conti (estradiol/dydrogesterone) prescribing and adverse event reporting information.
FEM-2021-0238 June 2021
Diabetes and frailty: guidance on the management of older adults with type 2 diabetes
Information intended for UK healthcare professionals only. This summary was developed by Guidelines and Dr Strain, based on the guidance developed by Strain WD et al., with the support of a sponsorship from Novo Nordisk UK.
Managing obesity in primary care
This management algorithm was developed by a multidisciplinary expert panel: Tahrani et al with the support of an educational grant from Novo Nordisk Limited. Information intended for UK healthcare professionals.
Osteoporotic fracture guideline
This guideline was developed by a multidisciplinary expert panel: Cooper C et al with the support of an educational grant from UCB Pharma Ltd.
Inhaler choice guideline
This management algorithm was developed by a multidisciplinary expert panel: Usmani et al and supported by Chiesi Ltd through the provision of a grant for its production.
Women of child-bearing age with inflammatory rheumatic diseases guideline
This guideline was developed by a multidisciplinary expert panel: Giles I et al with the support of an educational grant from UCB Pharma Ltd.
Consensus guideline on the holistic management of patients requiring anticoagulation
This guideline was developed by a multidisciplinary expert panel: Fay M et al with the support of an educational grant from Bayer plc.
Guideline for the managed introduction of biosimilar basal insulin
This guideline was developed by a multidisciplinary expert panel: Down S et al with the support of an educational grant from Mylan.
COPD: LAMA/LABA as initial maintenance therapy for appropriate symptomatic patients
This promotional resource has been funded and provided by GSK. Information intended for UK healthcare professionals only.
PM-GB-UCV-WCNT-200014 V3.0 | October 2021
Calculating renal function in patients with atrial fibrillation
This animation has been developed and funded by the Bristol Myers Squibb/Pfizer Alliance and is intended for UK healthcare professionals.
432-GB-2100230 June 2021
COPD: LAMA/LABA therapy—Real life case studies
This promotional resource has been funded and provided by GSK. Information intended for UK healthcare professionals only.
PM-GB-UCV-WCNT-200015 V2.0
Why you might want to review patients with COPD receiving a LAMA
This promotional resource has been funded and provided by GSK. Information intended for UK healthcare professionals only.
PM-GB-UCV-WCNT-200013
COPD: Have you done enough to implement guidelines?
This promotional resource has been funded and provided by GSK. Information intended for UK healthcare professionals only.
PM-GB-UCV-WCNT-200012
Why use LAMA/LABAs as initial maintenance therapy in specific COPD patients?
This promotional resource has been funded and provided by GSK. Information intended for UK healthcare professionals only.
PM-GB-UCV-WCNT-200011
LAMA/LABAs as initial maintenance therapy in COPD
This promotional resource has been funded and provided by GSK. Information intended for UK healthcare professionals only.
PM-GB-UCV-WCNT-200010
The role of peripherally acting µ-opioid receptor antagonists (PAMORAs) in the management of opioid-induced constipation (OIC)
This educational reference document has been initiated, commissioned, and developed by Sandoz Ltd. Information intended for UK healthcare professionals only.
View prescribing information
UK/MKT/RZM/20-0029f October 2020